The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. announced a first quarter 2026 update, revealing that the company anticipates its cash position will support operations into 2028.
The update includes positive data from its OCU410 program and the completion of enrollment for both OCU400 and OCU410ST clinical trials. The company also noted continued advancements toward submitting Biologics License Applications (BLA) for its gene therapy candidates. This positions Ocugen, Inc. to potentially accelerate its strategy in the competitive gene therapy sector.
Ocugen previously reported a 31 percent reduction in GA lesion growth with a medium dose of OCU410 in a Phase 2 trial. The company also asserted that OCU410 demonstrated nearly double the treatment effect compared to approved therapies in the same trial phase, along with safety and treatment effect advantages in earlier program updates. These findings support ongoing trial development and regulatory milestones.